Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection
D’Alise AM et al. Sci Transl Med 2022
Nouscom poster presentation of Full Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022
Nouscom Poster presentation at ASCO 2022, reporting the full Phase 1 Data of NOUS-209, an ‘off-theshelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors. NOUS-209 in [...]
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
Leoni G, D’Alise AM et al. Vaccines 2021
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
Leoni G et al, Cancer Research, 2020
Nouscom Poster presentation at CIMT 2022
Nouscom Poster presentation at CIMT 2022, reporting on the generation of a Modified Vaccinia Ankara (MVA) virus encoding IL-12 as a novel approach of “Vector Aided Microenvironment Programing: [...]
Nouscom Poster Presentation Of Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
Nouscom Poster presentation at AACR 2022, reporting on new translational Phase 1 data illustrating how NOUS-209, an off-the-shelf neoantigen immunotherapy, with pembrolizumab for treatment of [...]
New viral vectors for infectious diseases and cancer
Sasso E, D’Alise AM et al. Semin Immunol. 2020
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
D’Alise AM et al., Nature Comms, 2019
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome
Chang et al., JAMA Oncology, 2018
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
BASEL, Switzerland – 9th September 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the [...]
